IRIS
ARMUZZI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.612
AS - Asia 8.706
EU - Europa 2.786
SA - Sud America 1.682
AF - Africa 230
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 26.025
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.368
SG - Singapore 5.719
BR - Brasile 1.407
CN - Cina 1.202
VN - Vietnam 796
FI - Finlandia 544
DE - Germania 462
IE - Irlanda 421
FR - Francia 283
IN - India 253
IT - Italia 224
GB - Regno Unito 219
HK - Hong Kong 197
NL - Olanda 151
RU - Federazione Russa 128
CA - Canada 108
AR - Argentina 103
BD - Bangladesh 88
MX - Messico 83
NG - Nigeria 75
IQ - Iraq 64
SE - Svezia 57
PL - Polonia 53
ZA - Sudafrica 53
TR - Turchia 48
EC - Ecuador 46
BE - Belgio 41
ID - Indonesia 39
JP - Giappone 38
PK - Pakistan 36
CO - Colombia 34
ES - Italia 32
SA - Arabia Saudita 30
UA - Ucraina 29
VE - Venezuela 29
CZ - Repubblica Ceca 28
IR - Iran 24
UZ - Uzbekistan 23
MA - Marocco 22
CL - Cile 21
IL - Israele 20
TN - Tunisia 19
PY - Paraguay 18
KE - Kenya 16
LT - Lituania 16
AT - Austria 14
EG - Egitto 14
JO - Giordania 13
AE - Emirati Arabi Uniti 12
MY - Malesia 12
PE - Perù 12
NP - Nepal 11
DO - Repubblica Dominicana 10
RO - Romania 10
JM - Giamaica 9
PH - Filippine 9
PT - Portogallo 9
HN - Honduras 8
KZ - Kazakistan 8
OM - Oman 8
TT - Trinidad e Tobago 8
UY - Uruguay 8
CH - Svizzera 7
CR - Costa Rica 7
PS - Palestinian Territory 7
AU - Australia 6
AZ - Azerbaigian 6
DZ - Algeria 6
ET - Etiopia 6
GR - Grecia 6
KG - Kirghizistan 6
LV - Lettonia 6
AL - Albania 5
BG - Bulgaria 5
BY - Bielorussia 5
EE - Estonia 5
GT - Guatemala 5
LB - Libano 5
BA - Bosnia-Erzegovina 4
BO - Bolivia 4
CI - Costa d'Avorio 4
KW - Kuwait 4
RS - Serbia 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
HR - Croazia 3
MN - Mongolia 3
SC - Seychelles 3
SN - Senegal 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BH - Bahrain 2
BN - Brunei Darussalam 2
CY - Cipro 2
DK - Danimarca 2
KH - Cambogia 2
LU - Lussemburgo 2
MD - Moldavia 2
SI - Slovenia 2
Totale 25.999
Salva come PNG Salva come JPEG
Città #
Singapore 2.329
Chandler 1.819
Ashburn 1.570
San Jose 1.366
The Dalles 992
Dallas 903
Shanghai 624
Helsinki 541
Dublin 421
Boardman 402
Lawrence 393
Princeton 393
New York 308
Ho Chi Minh City 269
Los Angeles 232
Paris 216
Wilmington 202
Hanoi 201
Beijing 195
Falkenstein 187
Hong Kong 179
Amsterdam 140
São Paulo 130
Santa Clara 127
Pune 115
London 101
Benin City 71
San Mateo 70
Seattle 62
Council Bluffs 59
Rio de Janeiro 56
Ann Arbor 54
Milan 53
Warsaw 49
Orem 46
Buffalo 45
Phoenix 43
Moscow 42
Munich 41
Frankfurt am Main 40
Chennai 39
Brussels 38
Belo Horizonte 36
Brooklyn 34
Da Nang 34
Leawood 32
Montreal 32
Porto Alegre 31
Assago 30
Chicago 30
Curitiba 29
Mexico City 29
Toronto 28
Brasília 27
Haiphong 27
Tokyo 26
Johannesburg 25
Atlanta 24
Rome 24
San Francisco 23
Woodbridge 23
Brno 22
Fairfield 22
Tashkent 22
Charlotte 19
Guayaquil 19
Baghdad 18
Dhaka 18
Goiânia 18
Boston 17
Mumbai 17
Nairobi 16
Stockholm 16
Campinas 15
Guarulhos 15
Hillsboro 15
Houston 15
Poplar 15
Riyadh 15
Ankara 14
Manchester 14
Biên Hòa 13
Bắc Ninh 13
Amman 12
Oshnaviyeh 12
Quito 12
Bogotá 11
Denver 11
Erbil 11
Reston 11
Tunis 11
Columbus 10
Fortaleza 10
Kyiv 10
Madrid 10
Osasco 10
Berlin 9
Betim 9
Jeddah 9
Kingston 9
Totale 16.252
Salva come PNG Salva come JPEG
Nome #
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 620
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 191
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate 125
Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation 119
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 110
Adalimumab in active ulcerative colitis: A "real-life" observational study 108
13C-Breath Tests in the study of microsomal liver function 100
13C-breath tests in the study of mitochondrial liver function 99
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 98
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 98
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 98
Adalimumab in the treatment of immune-mediated diseases 95
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates 90
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 90
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 90
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 88
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 87
DNA mismatch repair gene mutations in hereditary non polyposis colorectal cancer (HNPCC) and putative HNPCC (P-HNPCC) Italian families 87
3-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure H-pylori infection 86
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 85
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 84
Acute pancreatitis and parathyroid carcinoma: a case report and literature review 82
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study 81
H-pylori poliantibiotic resistant strains in dyspeptic patients not eradicated by two consecutive triple eradication regimens 81
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 80
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 80
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study 79
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 78
Activity of Crohn's disease and small bowel contract-enhanced ultrasound findings 77
Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease 77
H-pylori gastric infection and rheumatic diseases 75
Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn's Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal Transition 75
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 75
Association of Depression With Incident Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis 75
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 74
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy 74
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 74
FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF alpha Agents 74
Antibiotic resistance of H-pylori strains obtained by dyspeptic patients not eradicated by two consecutive eradication regimens 73
Usefulness of C-13-methionine breath test as a non-invasive and dynamic tool to evaluate residual hepatic mitochondrial function 72
A novel pathogenic role for microvasculature in inflammatory bowel disease 72
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study 71
Haplotypic analysis of heat shock protein 70 (HSP70) single nucleotide polymorphisms (SNPs) in susceptibility and phenotype of inflammatory bowel disease (IBD) 71
The learning curve for using intestinal ultrasonography 71
Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study 71
HELICOBACTER-PYLORI GASTRITIS WITH CYTOTOXIN ASSOCIATED PROTEIN ANTIBODIES (CAGA) - A COMPUTER-AIDED EVALUATION OF INFLAMMATORY CELL INFILTRATION IN THE LAMINA PROPRIA, ATROPHIC GASTRITIS AND ACQUIRED MALT 71
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease 70
Family history of peptic ulcer and a positive C-13 urea breath test are predictive of gastroduodenal ulcer disease in uninvestigated dyspeptic patients 70
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study 70
Pomegranate Extract Affects Gut Biofilm Forming Bacteria and Promotes Intestinal Mucosal Healing Regulating the Crosstalk between Epithelial Cells and Intestinal Fibroblasts 70
Aminopyrine and methacetin 13C-breath tests to assess hepatic function in HCV-related chronic liver disease 69
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 69
Long-term scheduled therapy with infliximab in inflammatory bowel disease 68
Role of sucralfate in gastrointestinal diseases 68
Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis 68
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 68
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders 67
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study 67
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by C-13-octanoate breath test 67
C-13 urea breath test for predicting resistance to therapy in Helicobacter pylori infection 67
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study 67
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment 67
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 67
INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS ON ANTI TNF-ALPHA THERAPY: RESPONSE TO THE INFLUENZA A/H1N1 VACCINE 66
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study 66
Role of helicobacter pylori in gastroesophageal reflux disease 66
Non-invasive assessment of human hepatic mitochondrial function through the C-13-methionine breath test 66
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease 66
Incidence and symptoms related to Helicobacter pylori infection in dyspeptic patients 65
Dietary Fiber in Inflammatory Bowel Disease: Are We Ready to Change the Paradigm? 65
Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study 65
Helicobacter pylori eradication ameliorates migraine: An extended follow up study 65
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 65
IBD: Infliximab dose optimization in IBD-proactive or reactive? 65
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results 65
Disease patterns in late-onset ulcerative colitis: Results from the " IG-IBD ""AGED study""" 65
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 65
New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report 64
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 64
Patient Engagement in Health Management as a Mediator Between Perceived Risk and COVID-19 Related Distress in Patients With IBD: A Structural Equation Model 63
Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians 63
Occurence of systemic endothelial dysfunction in patients affected by ulcerative colitis and Crohn disease 63
Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD 63
The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars 63
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease 63
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study 63
New developments in biologics therapy: what about from the medical point of view? 62
Young GI angle: Should I go abroad? 62
Infliximab in the treatment of glucocorticoid-dependent ulcerative colitis: a 54 week randomized methylprednisolone-controlled trial 62
Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials 62
Apoptosis of epithelial cells in Helicobacter pylori associated chronic gastritis 62
Anti-CagA antibodies are associated with atrophic gastritis in a population at high gastric cancer risk: a morphometric study by computerized image analysis 62
C-13-methacetin breath test in patients with nonalcoholic steatohepatitis 62
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 62
Efficacy of a multistep strategy for Helicobacter pylori eradication 62
Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review 62
A multistep assessment of human liver mitochondrial function through C-13-ketoisocaproate and C-13-octanoate breath tests 62
Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD) 61
Hepatic mitochondrial function assessment through C-13-methionine and C-13-sodium octanoate breath tests 61
COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association 61
Totale 8.039
Salva come PNG Salva come JPEG
Categoria #
all - tutte 171.875
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 171.875
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202132 0 0 0 0 0 0 0 0 0 0 0 32
2021/2022240 6 2 11 47 3 0 7 27 20 20 53 44
2022/20235.250 848 55 426 576 434 552 7 536 968 459 335 54
2023/20243.358 220 322 786 260 112 386 184 110 26 218 337 397
2024/20254.584 95 27 49 56 40 444 223 298 913 1.257 601 581
2025/202612.383 1.825 832 898 1.073 462 703 3.765 616 661 800 402 346
Totale 26.190